Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults

NCT05884333 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05884333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05884333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 22, 2023
Completion date
May 22, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), chronic myelogenous leukemia (cml), myelodysplastic syndromes (mds), myeloproliferative disorder, non-hodgkin's lymphoma